The Hematology Society of Taiwan yesterday said acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, can progress quickly and aggressively and urged the government to ...
Targeted maintenance therapy with gilteritinib (Xospata; Astellas) following allogeneic hematopoietic stem cell ...
Cancer treatments can raise risk of therapy-related acute myeloid leukemia over time. A Japan study shows rising cases, stressing long-term monitoring while noting treatment benefits still outweigh ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...
MedPage Today on MSN
Big Jump in Therapy-Related AML Amid Growth in Population of Cancer Survivors
Study from Japan shows near-tripling over 30-year period ...
Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers ...
Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.
A US ecologic study finds higher cancer mortality in counties closer to nuclear plants, but results reflect association and ...
City of Hope’s participation in the 2026 AACR Annual Meeting, showcasing new research on cancer risk, immune resistance, metabolism and AI‑driven discovery.
Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Stocks to Buy for the Next Decade. On April 15, 2026, Eli Lilly and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results